Should We Back DTC in Europe? - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Should We Back DTC in Europe?

Pharmaceutical Technology Europe
Volume 23, Issue 1

Fedra Pavlou
This month, our columnist Nathan Jessop discusses a topic that remains highly debated in Europe; direct to consumer (DTC) advertising. This is a really interesting subject and, although there are many opponents to DTC in Europe, including many members of the pharmaceutical industry, it is still being discussed in European parliament. The primary reason for this is the pressure to improve access of information to patients, largely driven by the Internet phenomenon and patients' thirst for information and the need for a say in their treatment. This is of course no bad thing. I think it's great that patients are now able to take a more active role in their own healthcare and in learning about their conditions and treatments. But, there is an ongoing problem; the Internet is littered with information from unregulated sources and patients are largely unaware of the lack of reliability of some of those sources. This is indeed a problem and one that hasn't gone unnoticed by the regulators or industry but this isn't something that can be solved easily and will remain an issue for as long as there is free access to information; i.e. forever.

The question that Nathan asks this month, however, is whether pharmaceutical companies should actually be advertising directly to consumers about their brands or disease types. In other words, should we be following the American way? Our columnist provides a balanced argument but is largely not in favour of this movement for reasons of bias and lack of impartiality. I have to say, I fully agree with him. Perhaps there is a way that the pharmaceutical industry can get the right message across to patients because I am fully in favour of patient education; however, it's doing it the right way and I don't believe that blatant advertising is the way to go. Social media is one of the tools that is currently under review by several big pharma manufacturers, so too are patient group websites, online educational forums, etc. Our industry is still testing the water, quite rightly, with trepidation, but hopefully companies will hit on the right methods of communicating with patients that are hungry for information. My guess is that this will involve a holistic approach, where a number of online tools are used to deliver the right information. Question is, will patients be able to decipher the reliable sources from the unreliable ones? We've been chatting about this on our LinkedIn group ( already, why not join the discussion and let us know what you think?

For now, I would like to wish you a Happy New Year and all of the very best for a successful 2011.

Fedra Pavlou, Editor-in-Chief


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here